Take a look back at our most popular diabetes coverage for 2022.
Did you miss the top diabetes stories on Drug Topics® for 2022? Catch up on these noteworthy stories today.
One in 5 American adults with diabetes don't know that they have the disease.
A University of Houston study found that minorities have fewer eye exams, higher instances of disease.
A do-it-yourself option to replace traditional diabetes management technology is growing in popularity.
Overall numbers may be lower, but the obese, racial/ethnic minorities, and those without health care access have higher numbers of undiagnosed diabetes.
An analysis of real-world data from more than 6500 patients compared the risk of fracture for insulin, metformin, and a combination of insulin and metformin.
Used to treat a variety of concerns and found in many medicine cabinets, new research indicates that nonsteroidal anti-inflammatory drugs may pose a risk to patients with type 2 diabetes.
Novo Nordisk’s Saxenda (liraglutide) and Wegovy (semaglutide) are leading the way for a new crop of drugs that reduce appetite, but the cost-effectiveness is in question with many payers saying no to coverage.
New research suggests there was a 53% greater 5-year risk of cardiovascular disease in men with type 2 diabetes who received a GnRH agonist for prostate cancer compared with their counterparts who did not receive GnRH agonists.
It’s more important than ever to keep your team motivated and incentivized.
Over time, the emotional burden of managing the disease can become overwhelming.